Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_assertion type Assertion NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_head.
- NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_assertion wasGeneratedBy ECO_0000203 NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_provenance.
- NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_assertion wasDerivedFrom befree-2016 NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_provenance.
- NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_assertion SIO_000772 19864489 NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_provenance.
- NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_assertion evidence source_evidence_literature NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_provenance.
- NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_assertion description "[The clinical features of FXTAS, as well as various forms of clinical involvement in carriers without FXTAS, are thought to arise through a direct toxic gain of function of high levels of FMR1 mRNA containing the expanded CGG repeat.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772319.RAHLugByfmCesmXo87iMLGMiHjnkzOjm5SACAmJVUtvSU130_provenance.